Gene transfer technologies sit at the foundation of modern medicine's most ambitious projects. From engineering CAR-T cells to correcting hereditary mutations and delivering mRNA vaccines, the ability to introduce genetic material into cells with precision and efficiency now underpins entire therapeutic categories. As gene editing tools like CRISPR mature and regulatory bodies in the U.S., Europe, and Asia accelerate approvals, the infrastructure for gene delivery - viral vectors, lipid nanoparticles, electroporation platforms, and supporting reagents - has become one of biotech's most strategically contested spaces.
The Global Gene Transfer Technologies Market was valued at $4.2 billion in 2025 and is projected to reach $8.2 billion by 2031, expanding at a CAGR of 11.8% from 2026 to 2031. That growth reflects the compounding effect of rising disease burden, expanding clinical pipelines, and increasing commercial-scale manufacturing demand. Few sectors in life science are attracting comparable levels of investment from both private capital and public funding agencies such as the NIH and ARPA-H.
The companies shaping this market range from large diversified life science suppliers to focused clinical-stage developers. Each occupies a distinct position - some providing the raw materials and platforms that enable gene therapy manufacturing, others directly developing therapies, and others offering the analytical tools that keep production compliant and scalable. The ten companies profiled below represent the leading names across this value chain.
Viral vectors remain the dominant gene transfer modality, generating $2.5 billion in 2025 and holding a 59.4% market share. Their clinical track record - particularly AAV and lentiviral systems underlying most approved gene therapies - sustains this lead despite challenges around immunogenicity and manufacturing complexity. Gene therapy is the largest application at $1.5 billion and 36.2% of the market, driven by an expanding FDA and EMA approval pipeline and strong demand for one-time treatments for rare and chronic diseases. Cell therapy at $897.3 million and vaccine applications at $758.7 million round out a diversified application base with double-digit growth across each segment.
Non-viral vectors are the fastest-growing delivery mode at a 12.6% CAGR, propelled by lipid nanoparticle platforms carrying CRISPR and mRNA payloads. Electroporation leads physical methods with $231.8 million in revenue and a 12.4% CAGR, driven by its high transfection efficiency and suitability for CAR-T cell engineering. North America accounts for 49.9% of global revenue, with approximately 90% of that concentrated in the United States. Europe holds 27.6%, led by Germany, the U.K., and France. Asia-Pacific, at 17.8%, is the fastest-growing region, with Japan, China, and South Korea expanding their biotechnology sectors backed by government programs and fast-track regulatory frameworks.
• Headquarters: Waltham, Massachusetts, U.S.
• Founded: 1956
• Revenue: $44,556 million (FY2025)
• Employees: 125,000
• Focus: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services
Thermo Fisher is the largest revenue generator in the life sciences tools sector and a central supplier to the gene therapy manufacturing ecosystem. Its viral vector portfolio spans AAV, adenoviral, lentiviral, and retroviral systems. In 2025, the company partnered with Mirai Bio to advance nucleic acid therapeutics using its cGMP manufacturing infrastructure, and established a Cell and Gene Therapy Vision Center in South Korea, reflecting its commitment to geographic expansion in the Asia-Pacific region.
• Headquarters: Darmstadt, Germany
• Founded: 1668
• Revenue: $23,866.8 million (FY2025)
• Employees: 62,461
• Focus: Healthcare, Life Science Solutions and CDMO Services, Electronics
Merck KGaA operates across healthcare, life science, and electronics, with its Life Science segment playing a direct role in gene transfer through transfection reagents, process solutions, and contract services. The 2024 acquisition of Mirus Bio for approximately $600 million added the TransIT-VirusGEN transfection reagent line and bolstered end-to-end viral vector production capabilities. With $2.73 billion invested in R&D during FY2025, Merck KGaA continues to compete across CRISPR-based therapies and mRNA vaccine supply chains.
• Headquarters: Hercules, California, U.S.
• Founded: 1952
• Revenue: $2,583.2 million (FY2025)
• Employees: 7,450
• Focus: Life Science research tools including digital PCR, electroporation, and transfection; Clinical Diagnostics
Bio-Rad's relevance to gene transfer lies primarily in quality analytics and upstream research tools. Its droplet digital PCR platform is used for AAV vector titer measurement and lentiviral batch release - applications increasingly critical as gene therapy manufacturers navigate regulatory submissions. The recent acquisition of Stilla Technologies and the launch of Serotype 2 and 8 kits extend Bio-Rad's ddPCR capabilities. A partnership with CCRM Nordic targets ATMP translation across the Nordics and Europe.
• Headquarters: Oxford, U.K.
• Founded: 1995
• Revenue: $169.8 million (FY2025)
• Employees: 986
• Focus: Lentiviral vector manufacturing, Cell and gene therapy CDMO services
Oxford Biomedica is one of the few pure-play CDMOs in the cell and gene therapy space, with deep expertise in lentiviral vector production. Its 2026 Commercial Supply Agreement with Bristol Myers Squibb for CAR-T programs builds on a partnership that dates to 2020. The 2024 acquisition of ABL Europe SAS from Institut Mérieux expanded OXB's footprint across the U.S., U.K., and EU. A 2025 acquisition of an RTP, North Carolina manufacturing facility further strengthens its U.S. commercial capacity.
• Headquarters: Goettingen, Germany
• Founded: 1870
• Revenue: $4,001.7 million (FY2025)
• Employees: 14,042
• Focus: Bioprocess Solutions, Lab Products and Services
Sartorius is a critical upstream supplier to cell and gene therapy manufacturers, providing bioreactors, filtration, and - following the 2023 acquisition of Polyplus - transfection reagents for viral vector production. The company has opened a new GMP transfection reagent facility in Illkirch, France and is expanding manufacturing capacity in India with a new single-use bioreactor production line planned for 2027. Recurring consumables within the Bioprocess Solutions division drove 7.6% constant-currency sales growth in 2025.
• Headquarters: Venlo, The Netherlands
• Founded: 1984
• Revenue: $2,090 million (FY2025)
• Employees: 5,654
• Focus: Molecular Diagnostics, Life Sciences Research, Sample Preparation, Bioinformatics, Applied Testing
Qiagen contributes to gene transfer workflows primarily through its sample preparation and digital PCR capabilities. In 2025, the company introduced an enhanced dPCR workflow for lentivirus-based applications, providing high-precision analytics for CAR-T process development, batch release, and regulatory compliance. Its platforms serve pharmaceutical developers, academic researchers, and clinical diagnostic labs, making Qiagen a supporting technology provider across multiple gene therapy manufacturing steps.
• Headquarters: Rockville, Maryland, U.S.
• Founded: 1998
• Revenue: $33 million (FY2025)
• Employees: 114
• Focus: Flow Electroporation Technology, ExPERT Platform, GMP Cell Engineering Solutions
MaxCyte occupies a focused niche in electroporation-based cell engineering, a segment generating $231.8 million in 2025 at a 12.4% CAGR. Its ExPERT platform supports applications from early research through GMP-scale CAR-T manufacturing. A 2026 product launch - the ExPERT DTx - introduced a modular 96-well high-throughput transfection system for primary cells and cell lines. A licensing agreement with Adicet Bio for allogeneic gamma delta T cell therapy development illustrates the platform's growing commercial reach.
• Headquarters: Basel, Switzerland
• Founded: 1897
• Revenue: $7,879.9 million (FY2025)
• Employees: 16,866
• Focus: Viral vector manufacturing, Plasmid DNA production, Cell and gene therapy CDMO services
Lonza is one of the leading CDMOs in cell and gene therapy, with manufacturing capabilities spanning lentiviral, AAV, adenoviral, and oncolytic viral vectors, as well as plasmid DNA. Its platforms are designed to maximize vector yield, potency, and purity at commercial scale. Lonza's breadth of service - from early development through commercial supply - positions it as a preferred manufacturing partner for developers seeking to outsource complex gene therapy production.
• Headquarters: Somerset, New Jersey, U.S.
• Focus: Contract development and manufacturing, Viral vector and gene therapy production
Catalent Biologics is a contract development and manufacturing organization with established capabilities in viral vector and gene therapy production. In December 2024, Novo Holdings completed its acquisition of Catalent Inc., consolidating the company's CDMO capabilities within a major life science investment group. This transaction positions Catalent's manufacturing infrastructure within a broader portfolio strategy aimed at scaling cell and gene therapy production capacity as commercial demand for approved therapies grows.
• Headquarters: Shirley, New York, U.S.
• Founded: 2005
• Focus: Gene therapy vector design, Viral and non-viral vector development, Lipid nanoparticle solutions, RNA therapeutics, Cell and gene therapy products and services
Creative Biolabs serves biotechnology startups, pharmaceutical companies, and academic research teams seeking specialized support across the gene therapy development continuum. The company has expanded its offerings to include complete lipid nanoparticle solutions for mRNA vaccine and gene editing applications, as well as circRNA and nucleic acid analysis platforms covering early discovery through preclinical development. Its service model focuses on addressing technical challenges in viral vectors, non-viral vectors, and RNA therapeutics for translational teams.
The Global Gene Transfer Technologies Market is being built out by a diverse group of companies - large platform suppliers, specialized CDMOs, electroporation technology developers, and clinical-stage gene therapy companies - each contributing a distinct capability to an interconnected ecosystem. The transition from research-scale to commercial-scale gene therapy is generating sustained demand across every layer of this value chain, from vector manufacturing and transfection reagents to quality analytics and precision delivery systems.
Competitive differentiation in this market will increasingly depend on manufacturing scale, regulatory readiness, and the ability to integrate emerging tools like AI-assisted vector design and next-generation LNP chemistry into production workflows. Companies that can address the persistent bottlenecks around cost, workforce, and immunogenicity while maintaining compliance with evolving FDA and EMA frameworks will be best positioned to capture growth as the market approaches $8.2 billion by 2031.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.